Core Viewpoint - The company has decided to adjust its development strategy for the biosimilar BAT3306, originally planned to terminate the BAT3306-2 study, in response to the latest technical guidance from the FDA and EMA [1] Group 1: Development Strategy - The company will conduct new registration clinical studies comparing BAT3306 with US-approved Keytruda in non-small cell lung cancer patients during the IB-IIIA phase [1] - The adjustment in strategy will not affect the fundraising investment plans or harm the interests of the company and its shareholders [1]